Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID-19 days

Dermatol Ther. 2020 Jul;33(4):e13415. doi: 10.1111/dth.13415. Epub 2020 May 2.

Authors

Lavinia Agra Coletto^{1

2}, Ennio Giulio Favalli², Roberto Caporali^{1

2}

Affiliations

¹ Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, University of Milan, Milan, Italy.
² Department of Clinical Rheumatology, ASST G. Pini & CTO, Milan, Italy.

No abstract available

Publication types

Letter
Comment

MeSH terms

Arthritis, Psoriatic* / diagnosis
Arthritis, Psoriatic* / drug therapy
Betacoronavirus
COVID-19
Coronavirus Infections*
Humans
Immunosuppressive Agents / adverse effects
Pandemics*
Pneumonia, Viral*
Psoriasis* / diagnosis
Psoriasis* / drug therapy
SARS-CoV-2

Substances

Immunosuppressive Agents